a) GTT in WT mice with CNO (ip, 3 mg/kg) or vehicle (10%DMSO). Right: Cumulative blood glucose change (AUC, 0′ to 120′). N = 10. Blood glucose in male ChAT-IRES-cre/AAV8-Syn-DIO-hM3D(Gq)-mCherry (N = 5) and ChAT-IRES-cre/AAV8-hSyn-DIO-mCherry (N = 8). b) After 6 h fasted with CNO treatment (3 mg/kg ip) over 240 mins. Right: cumulative blood glucose change (AUC, 0′ to 240′). c) During GTT after 6 h fast (vehicle at −30min, glucose 2 mg/kg at 0 min). Right: cumulative blood glucose change (AUC, 0′ to 120′). d) During GTT after 6 h fast (CNO at −180min, glucose 2 mg/kg at 0 min). Right: cumulative blood glucose change (AUC, 0′ to 120′). Blood glucose in female CNO-treated ChAT-IRES-cre/AAV8-hSyn-DIO-hM3D(Gq)-mCherry (N = 5) and ChAT-IRES-cre/AAV8-hSyn-DIO-mCherry (n = 7) mice (CNO: 3 mg/kg, intraperitoneal). e) After 6 h fast. Right: cumulative blood glucose change (AUC, 0′ to 120′). f) During ITT (CNO at −30min, Insulin 0.25U/kg i.p. at 0 min). g) During GTT after 6 h fast (CNO at −30min, glucose 2 mg/kg at 0 min). h) During GTT with atropine methyl nitrate (2 mg/kg, i.p.). i) During GTT after 6 h fast (CNO at −180min, glucose 2 mg/kg at 0 min). j) Cumulative blood glucose change (AUC, 0′ to 120′) during GTT. k) Cumulative blood glucose change (AUC, 0′ to 120′) during GTT with atropine. l) Cumulative blood glucose change (AUC, 0′ to 120′) during GTT 180 mins after CNO. m) Plasma insulin during GTT at −30, 0, and 10 mins. n) Plasma glucagon during GTT at −30, 0, 10, 30, 60 and 90 mins. o) Plasma glucagon during ITT at −30, 0, 10, 30, and 60 mins. Statistical analyses are described in Supplementary Table 3.